Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary assessment of oral grass pollen-derived peptides (gpASIT+TM) for seasonal allergic rhinoconjunctivitis
2008-006369-10Phase 2Completed
- Sponsor
- TOOLS Life Science
- Start
- Jan 2009
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of gpASIT+ in seasonal allergic rhinitis (SAR) (3 arms), sponsored by TOOLS Life Science. Primary endpoint: Clinical tolerability and safety of gpASIT+TM. Started Jan 2009; status: completed.
02
Drugs
gpASIT+
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2008-006369-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006369-10.